Fast Pod growth, harder factory math
- Q1 2026 revenue rose 33.9% to $761.7 million, led by Omnipod growth in the U.S. and abroad.
- Omnipod made up 99.6% of Q1 2026 revenue, so this is mainly a one-platform story.
- Management raised full-year 2026 revenue growth guidance to 21% to 23%, even after a device correction.
- Adjusted gross margin was 71% in Q1, down 90 basis points from last year, due to correction and transition costs.
- About 40% of new customer starts in Q1 came from Type 2 diabetes, a key new market for Omnipod 5.
Demand is winning, factories must catch up
Insulet is still growing fast. Q1 2026 revenue rose 33.9% to $761.7 million, and management raised full-year 2026 revenue growth guidance to 21% to 23%. That is a strong signal that demand for Omnipod 5 is still healthy.
The best part of the story is market expansion. International Omnipod revenue grew 59.4% in Q1 2026, or 45.2% in constant currency, which strips out currency moves. About 40% of new customer starts came from people with Type 2 diabetes, showing that the newer indication is already important.
The harder part is execution. Q1 GAAP gross margin was 69.5%. Management said the voluntary medical device correction cost about $12 million in the quarter, while product transition costs also hurt margin. The company estimates the total correction and related costs will be about $30 million, with more than half expected in 2026 and the rest in 2027.
So the public case is balanced. Insulet has a large market, sticky users, and recurring Pod sales. But the stock also depends on the company proving it can make complex disposable devices at huge scale without repeat quality issues.
A medical razor and blades model
Insulet sells the Omnipod platform for insulin delivery. Users wear a small tubeless pump called a Pod, which delivers insulin and is replaced after up to three days. That creates repeat revenue instead of mostly one-time device sales.
The pay-as-you-go model lowers the upfront cost for patients and insurers. It can also make the product easier to try than a traditional pump with a larger initial device cost.
The moat comes from tubeless design, patents, insurance coverage, and habit. Diabetes devices become part of daily life, so switching can be hard once a patient, doctor, and payor are used to a system.
The weak point is concentration. Omnipod was 99.6% of Q1 2026 revenue. If quality, supply, reimbursement, or competition hurts Omnipod, there is little else in the company big enough to offset it.
Omnipod 5 carries the company
Omnipod 5
This is Insulet's flagship automated insulin delivery system. It connects with third-party continuous glucose monitors, which are sensors that track blood sugar through the day.
Type 2 diabetes indication
The FDA cleared Omnipod 5 for adults with Type 2 diabetes in 2024. Management said about 40% of Q1 2026 new customer starts came from Type 2 users.
Sensor integrations
Insulet is adding more sensor choice, including Dexcom G7 and Abbott FreeStyle Libre 2 Plus in various markets. Libre 3 Plus integration is a next catalyst because management says it can open a market of nearly 450,000 new users.
Omnipod Discover
Launched in 2026, Omnipod Discover is a data and reporting platform for Omnipod 5 users, caregivers, and health care providers. It can help users and doctors see blood sugar patterns.
Omnipod DASH and Classic Omnipod
These older generations support existing users, but the company is shifting attention to Omnipod 5. Classic Omnipod is being phased out.
Drug Delivery
This small line uses Pod technology for partners, including Amgen's Neulasta Onpro kit. It was only 0.4% of Q1 2026 revenue and declined 77.9% year over year.
Nearly all revenue is Omnipod
The mix uses revenue for the three months ended March 31, 2026. Omnipod was 99.6% of revenue, split between U.S. Omnipod at 67.7% and International Omnipod at 31.9%.
What could break the story
Repeat Pod quality issue
High impact · Medium oddsIn March 2026, Insulet started a voluntary medical device correction for certain Omnipod 5 lots because a manufacturing defect could cause insulin leakage inside the Pod and lead to under-delivery. Management said it made targeted fixes, but the event shows how hard it is to make complex disposable medical devices at scale.
Gross margin does not recover
High impact · Medium oddsQ1 2026 GAAP gross margin was 69.5%, below 71.9% in Q1 2025. Adjusted gross margin was 71%, down 90 basis points year over year, hurt by the device correction and excess and obsolescence costs tied to new Pod configurations.
Single-platform dependence
High impact · Medium oddsOmnipod made up 99.6% of Q1 2026 revenue. This focus helps Insulet scale, but it also means a reimbursement change, supply problem, or competitor win can hit the whole company.
Type 2 users do not stay engaged
Medium impact · Medium oddsType 2 diabetes is a major growth path, and about 40% of Q1 2026 new customer starts came from that group. The open question is whether these users keep using Pods at strong rates after the first start.
Tariff exemption risk
Medium impact · Medium oddsA U.S. Department of Commerce Section 232 investigation began in September 2025 and could remove current tariff exemptions for certain medical devices, including insulin pumps. That could raise costs and pressure margins.
In one breath
What does Insulet sell?
Insulet sells Omnipod, a tubeless insulin pump system. The main product is Omnipod 5, which can adjust insulin delivery using data from a continuous glucose monitor.
Why are Pods recurring revenue?
Each Pod is disposable and is used for up to three days before replacement. That means the company earns repeat sales as active users keep ordering Pods.
Why did Insulet's margin fall in Q1 2026?
Q1 2026 gross margin fell because of a voluntary medical device correction and costs from switching to new Pod configurations. Management said the correction cost about $12 million in Q1 and estimated about $30 million of total correction and related costs.
Why does Type 2 diabetes matter for Insulet?
The Type 2 market is much larger than the traditional pump market for Type 1 diabetes. Omnipod 5 was cleared for adults with Type 2 diabetes in 2024, and about 40% of Q1 2026 new customer starts came from Type 2 users.